IRIS
GERRATANA, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.792
AS - Asia 3.760
EU - Europa 1.963
SA - Sud America 551
AF - Africa 84
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 13.157
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.666
SG - Singapore 1.821
CN - Cina 704
BR - Brasile 449
IT - Italia 392
HK - Hong Kong 380
DE - Germania 369
VN - Vietnam 347
RU - Federazione Russa 197
UA - Ucraina 181
FR - Francia 168
IN - India 156
GB - Regno Unito 119
FI - Finlandia 88
IE - Irlanda 84
SE - Svezia 69
CA - Canada 63
TR - Turchia 53
KR - Corea 45
NL - Olanda 42
PL - Polonia 40
AR - Argentina 39
JP - Giappone 39
AT - Austria 36
BE - Belgio 34
BD - Bangladesh 32
CZ - Repubblica Ceca 31
IQ - Iraq 30
MX - Messico 30
ZA - Sudafrica 29
ES - Italia 27
PK - Pakistan 17
CH - Svizzera 16
ID - Indonesia 16
LT - Lituania 16
RO - Romania 16
CO - Colombia 13
EC - Ecuador 12
IR - Iran 12
SA - Arabia Saudita 12
VE - Venezuela 12
EG - Egitto 11
UZ - Uzbekistan 10
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 8
MA - Marocco 8
PY - Paraguay 8
CL - Cile 7
DZ - Algeria 7
IL - Israele 6
JM - Giamaica 6
TH - Thailandia 6
TN - Tunisia 6
BO - Bolivia 5
EE - Estonia 5
LB - Libano 5
LV - Lettonia 5
NP - Nepal 5
PH - Filippine 5
DK - Danimarca 4
HN - Honduras 4
JO - Giordania 4
KZ - Kazakistan 4
LA - Repubblica Popolare Democratica del Laos 4
NO - Norvegia 4
OM - Oman 4
PA - Panama 4
SN - Senegal 4
TG - Togo 4
UY - Uruguay 4
AL - Albania 3
AM - Armenia 3
EU - Europa 3
HU - Ungheria 3
MY - Malesia 3
NI - Nicaragua 3
RS - Serbia 3
SY - Repubblica araba siriana 3
AU - Australia 2
BB - Barbados 2
BG - Bulgaria 2
BS - Bahamas 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
GR - Grecia 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
MN - Mongolia 2
PE - Perù 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
Totale 13.131
Salva come PNG Salva come JPEG
Città #
Ashburn 916
Singapore 857
Fairfield 716
Chandler 446
Hong Kong 376
Woodbridge 346
San Jose 322
Seattle 306
Beijing 304
Houston 277
Wilmington 243
Cambridge 227
Ann Arbor 207
Frankfurt am Main 156
Los Angeles 148
Boardman 145
Lauterbourg 126
New York 118
Dearborn 115
Council Bluffs 102
Jacksonville 98
Ho Chi Minh City 96
Dublin 79
Dallas 77
Princeton 76
Munich 69
Buffalo 66
Hanoi 66
Dong Ket 64
The Dalles 57
Udine 54
Hefei 50
Santa Clara 47
São Paulo 47
Redondo Beach 42
Seoul 42
San Diego 40
Warsaw 38
Tokyo 37
Washington 35
Montreal 34
Helsinki 32
Orem 32
Brussels 29
Stockholm 28
Izmir 27
Martignacco 26
Redmond 26
Brno 25
Denver 25
London 25
Ogden 25
Chennai 24
Des Moines 23
Nuremberg 22
Phoenix 22
Turku 22
Brooklyn 20
Milan 20
Chicago 19
Johannesburg 19
Belluno 18
Vienna 17
Boston 16
Guangzhou 16
Poplar 16
Amsterdam 15
Da Nang 15
Shanghai 15
Zurich 15
Manchester 14
Rome 14
Lappeenranta 13
Mexico City 13
Mumbai 13
San Francisco 13
Ankara 12
Baghdad 12
Falls Church 12
Hyderabad 12
Nanjing 12
Newark 12
Norwalk 12
Atlanta 11
Düsseldorf 11
Naples 11
Trieste 11
Belo Horizonte 10
City of London 10
Jinan 10
Leawood 10
New Delhi 10
Arezzo 9
Augusta 9
Changsha 9
Charlotte 9
Spinea 9
Tashkent 9
Timisoara 9
Toronto 9
Totale 8.631
Salva come PNG Salva come JPEG
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 222
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 211
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 194
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 188
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 187
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 186
Pattern of metastasis and outcome in patients with breast cancer 184
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 180
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 179
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 175
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 175
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 172
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 170
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 167
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 167
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 164
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 161
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 157
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 156
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 156
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 155
International expert consensus on the clinical integration of circulating tumor cells in solid tumors 151
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 149
Do platinum salts fit all triple negative breast cancers? 149
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 149
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 147
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 147
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 145
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 140
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 139
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 136
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 134
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 134
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 133
Determinants of Last-line Treatment in Metastatic Breast Cancer 130
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 129
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 129
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 128
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 127
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 127
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 126
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 126
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 125
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 125
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 123
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 123
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 122
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 121
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 121
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 120
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 117
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 114
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 114
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 112
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 112
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 112
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 111
Risk factors and survival outcomes in patients with brain metastases from breast cancer 107
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 107
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 106
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 104
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 104
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 103
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 99
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 98
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 93
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics 92
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 92
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 92
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 92
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling 90
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 90
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 88
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 87
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 86
null 84
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 84
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 84
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 83
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China 82
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 78
Time to surgery after neoadjuvant chemotherapy for early breast cancer 78
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 77
The puzzling clinical presentation of fluoropyrimidines cardiotoxicity 76
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 72
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 72
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 69
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach 68
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology 68
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 67
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 66
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 66
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools 66
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies 66
The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives 65
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects 64
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 64
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them 64
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report 62
Landscape of circulating tumour DNA in metastatic breast cancer 62
Totale 11.870
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.191
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.191
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021308 0 0 0 0 0 0 0 0 0 69 108 131
2021/2022753 88 69 15 14 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024715 45 29 56 30 118 193 9 19 43 25 30 118
2024/20252.566 130 158 97 107 186 119 175 145 315 172 413 549
2025/20265.094 576 516 382 562 867 573 658 214 419 327 0 0
Totale 13.628